MARKET

TCON

TCON

TRACON Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.750
+0.060
+3.55%
Opening 15:12 04/08 EDT
OPEN
1.740
PREV CLOSE
1.690
HIGH
1.780
LOW
1.670
VOLUME
42.35K
TURNOVER
--
52 WEEK HIGH
15.80
52 WEEK LOW
0.9500
MARKET CAP
9.45M
P/E (TTM)
-0.2331
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average TCON stock price target is 6.67 with a high estimate of 11.00 and a low estimate of 3.000.

EPS

TCON News

More
  • TRACON Announces May 8 Date for Type B Teleconference Meeting with FDA to Discuss Trial Design for ENVASARC: A Potential Pivotal Study of Envafolimab in Sarcoma
  • GlobeNewswire · 2d ago
  • TRACON Announces May 8 Date For Type B Teleconference Meeting With FDA To Discuss Trial Design For ENVASARC: A Potential Pivotal Study Of Envafolimab In Sarcoma
  • Benzinga · 2d ago
  • TRACON Pharmaceuticals Announces Appointment of Saundra Pelletier to Board of Directors
  • GlobeNewswire · 03/19 13:15
  • Edited Transcript of TCON earnings conference call or presentation 27-Feb-20 9:30pm GMT
  • Thomson Reuters StreetEvents · 03/18 08:29

Industry

Biotechnology & Medical Research
+3.18%
Pharmaceuticals & Medical Research
+3.10%

Hot Stocks

Symbol
Price
%Change

About TCON

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company's research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company's lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.
More

Webull offers kinds of TRACON Pharmaceuticals Inc stock information, including NASDAQ:TCON real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TCON stock news, and many more online research tools to help you make informed decisions.